Neo-Sequence 2：NCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGC
- Conditions
- Diffuse Type CarcinomaGastric Cancer
- Interventions
- Drug: Albumin paclitaxel+SOX+BEV+ PD-1 monoclonal antibody therapy
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-04-17
- Target Recruit Count
- 67
- Registration Number
- NCT06371586
- Locations
- 🇨🇳
Cancer hospital，Chinese acadamy of medical sciences, Beijing, China
Transhiatal Tunnel Valvuloplasty for Reconstruction Following the Laparoscopic Proximal Gastrectomy
- Conditions
- Gastric Cancer
- Interventions
- Procedure: the Transhiatal Tunnel Valvuloplasty technique
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2024-04-10
- Target Recruit Count
- 30
- Registration Number
- NCT06354036
- Locations
- 🇨🇳
Department of Pancreatic and Gastric Surgical Oncology, National Cancer Center/ National Clinical Research for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Short-term and Long-term Outcomes of Colorectal Cancer Treated With Natural Orifice Specimen Extraction Surgery : a National Registry-based Study
- Conditions
- Colorectal Cancer
- Interventions
- Procedure: Natural orifice specimen extraction
- First Posted Date
- 2024-04-05
- Last Posted Date
- 2024-04-05
- Target Recruit Count
- 8000
- Registration Number
- NCT06350370
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study
- Conditions
- Borderline Resectable Pancreatic Cancer
- Interventions
- Drug: Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate in combination with CamrelizumabDrug: Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-04-03
- Target Recruit Count
- 40
- Registration Number
- NCT06345300
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijin, China
Response Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related HNSCC
- Conditions
- Head and Neck Cancer
- Interventions
- Radiation: radical radiotherapy (70Gy)Radiation: radical radiotherapy (66Gy)Radiation: radical radiotherapy (60Gy)Combination Product: anti-PD-1 or PD-L1 antibody
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-04-03
- Target Recruit Count
- 133
- Registration Number
- NCT06345287
- Locations
- 🇨🇳
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, CAMS & PUMC, Beijing, China
Safety and Efficacy of Intravenous IDOV-SAFETM in Patients With Advanced Solid Tumors
- Conditions
- Neoplasms
- Interventions
- Biological: Oncolytic Virus injection(IDOV-SAFETM)
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2025-02-04
- Target Recruit Count
- 19
- Registration Number
- NCT06346041
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma
- Conditions
- Locally Advanced Esophageal Squamous Cell CarcinomaSintilimabRadiotherapyConcurrent ChemoradiotherapyImmunonutrition
- Interventions
- Radiation: RadiotherapyDrug: Programmed Cell Death Protein 1 InhibitorDietary Supplement: Immunonutrition support
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2024-06-11
- Target Recruit Count
- 57
- Registration Number
- NCT06342167
- Locations
- 🇨🇳
Department of Radiation Oncology，Clinical Oncology School of Fujian Medical University，Fujian Cancer Hospital, Fujian, Fujian, China
🇨🇳Department of Radiation Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, Beijing, China
🇨🇳Department 1st of Radiation Oncology, Anyang Tumor Hospital, Anyang, Henan, China
Real-world Clinical Outcomes of NSCLC Patients Receiving Neoadjuvant Immunotherapy
- Conditions
- NSCLC
- Interventions
- Drug: Neoadjuvant immunotherapyDrug: Other drugs for neoadjuvant treatment
- First Posted Date
- 2024-03-19
- Last Posted Date
- 2024-07-03
- Target Recruit Count
- 4000
- Registration Number
- NCT06317558
- Locations
- 🇨🇳
Shugeng Gao, Beijing, Beijing, China
Quantitative Evaluation of the Impact of Relaxing Eligibility Criteria for Lung Cancer Based on Real-world Data
- Conditions
- Lung Cancer
- First Posted Date
- 2024-03-18
- Last Posted Date
- 2024-03-18
- Target Recruit Count
- 50000
- Registration Number
- NCT06314542
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
Constructing a Multimodal Imaging System to Predict the Risk of Heterochronous Metastasis of Rectal Cancer
- Conditions
- Distant MetastasisLocally Advanced Rectal Cancer
- Interventions
- Other: No intervention was administrated to the two cohorts.
- First Posted Date
- 2024-03-05
- Last Posted Date
- 2024-03-05
- Target Recruit Count
- 302
- Registration Number
- NCT06293612
- Locations
- 🇨🇳
National Cancer Center, National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China